Exploring how TP53 mutations affect ovarian cancer risk
Understanding the role of TP53 mutation in genetic susceptibility to ovarian cancer
This study is looking at how certain changes in the TP53 gene might affect women with BRCA1 and BRCA2 mutations, who are at a higher risk for ovarian cancer, to help find better ways to detect and prevent the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11065542 on NIH RePORTER |
What this research studies
This research investigates the role of TP53 mutations in women who carry BRCA1 and BRCA2 mutations, which significantly increase their risk of developing ovarian cancer. The study aims to understand the biological mechanisms behind this susceptibility by using advanced sequencing techniques to detect TP53 mutations in various biological samples. By analyzing these mutations in peritoneal fluid and Pap test DNA, the research seeks to uncover how these mutations contribute to the development of ovarian cancer, particularly in women with and without existing cancer. The findings could provide insights into early detection and prevention strategies for at-risk women.
Who could benefit from this research
Good fit: Ideal candidates for this research include women with BRCA1 or BRCA2 mutations, particularly those who are at high risk for developing ovarian cancer.
Not a fit: Patients without BRCA mutations or those who do not have a family history of ovarian cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved screening and preventive measures for women at high risk of ovarian cancer.
How similar studies have performed: Similar research has shown promising results in understanding the genetic factors contributing to cancer risk, indicating that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Risques, Rosa Ana — University of Washington
- Study coordinator: Risques, Rosa Ana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.